Using pro-apoptotic drugs to improve treatments for pulmonary tuberculosis
Official title: Pro-apoptotic Drugs as Host-Directed Treatments for Pulmonary Tuberculosis
Funded at Johns Hopkins University · NIH-11101929 · Data updated 2026-11-12
This study is looking at how a drug called navitoclax can help improve treatment for people with pulmonary tuberculosis (TB) by helping to get rid of infected cells, which could lead to better lung health and shorter treatment times.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | February 24, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $774,881 |
| NIH project number | 1R01AI190038-01 |
| Project ID | NIH-11101929 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pulmonary tuberculosis who are undergoing treatment.
✕Less likely to help
Patients with non-pulmonary forms of tuberculosis or those who have already experienced severe lung damage may not benefit from this research.
What this research studies
This research investigates the use of pro-apoptotic drugs, specifically navitoclax, to enhance the treatment of pulmonary tuberculosis (TB). By promoting the death of infected cells, these drugs aim to reduce tissue damage and inflammation caused by TB, which can lead to chronic lung issues. The study will explore how these drugs can improve the effectiveness of existing TB treatments and prevent long-term complications associated with the disease. Patients may benefit from a shorter treatment duration and improved lung health.
Why it matters
Potential benefit: If successful, this research could lead to more effective TB treatments and better long-term lung health for patients.
How similar studies have gone: Previous research has shown promising results with similar approaches using pro-apoptotic therapies in other conditions, suggesting potential for success in this area.
Where this research is happening
-
Johns Hopkins University
Baltimore, United States Active
Researchers
- Principal investigator: Jain, Sanjay — Johns Hopkins University
- Study coordinator: Jain, Sanjay
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.